A plethora of evidence has demonstrated the safety and efficacy of statins to notably reduce low-density-lipoprotein cholesterol (LDL-C) and the risk of atherosclerotic cardiovascular disease (ASCVD). However, a consequential risk remains in patients treated with statins to switch to other lipid-lowering therapies. Studies have also shown remarkable conclusions that suggest the use of one statin in combination with other molecules in hopes of reducing this residual risk. Thus, to gain a better understanding of the risks and opportunities in statin therapy, Docplexus, in collaboration with the Care Institute Of Medical Sciences- Joint International Conference (CIMS-JIC), has organized an exclusive case-based webinar on 31 st August 2020, 7:00 PM onwards.
Come, be a part of this webinar and get all your queries answered. Stay tuned!!! The speakers for this webinar are: - Dr. Urmil…
